Oncology Tube Oncology Tube RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ECOG Trial in Smoldering MM
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School provides results from the ECOG trial in smolde... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Isatuximab as a Treatment Option for MM
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School considers whether isatuximab can remain a treat... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Progression-Free Survival in MM when Treating with Isatuximab
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School discusses the prolonged progression-free surviv... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Drug Pricing Policies Proposed
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology addresses the policies proposed to drig pricing. Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Transition from Volume to Value
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in the oncology space. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Cost Factors in Novel Therapeutic Interventions
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel therapeutic interventions. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

The Role of CDK 4/6 Inhibitors in Advanced Breast Cancer
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology explains the role of CDK 4/6 inhibitors in advanced breast cancer and discusses whether they are inte... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

ImPasstion130 Trial in TNBC
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the results of the ImPassion130, a phase III study that adds atezolizumab to 1st line chemothe... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

MONALEESA-7 Trial Implications
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in premenopausal, metastatic breast cancer. Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

KEYNOTE-365 in mCRPC Results
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of KEYNOTe-365, pembrolizumab in metastatic castration-resistant prostate cancer ... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Upcoming Prostate Cancer PARP Inhibitor Trials
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming prostate cancer PARP inhibitor trials. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

The Role of Biomarker Selection Trials in Prostate Cancer
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients. Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Difference in ENZAMET and TITAN Studies
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between the ENZAMET and TITAN studies. <br /> Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Outcomes from the TITAN Study in mCSPC
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of the TITAN study in metastatic castration-sensitive prostate cancer (mCSPC).<br />... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts

Strategies for Treating 2nd Line RCC Patients
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber Cancer Institute discusses strategies for ... Author: obr Added: 07/01/2019 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2019 Category: Cancer & Oncology Source Type: podcasts